FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310332458> ?p ?o ?g. }

• W4310332458 endingPage "175883592211367" @default.
• W4310332458 startingPage "175883592211367" @default.
• W4310332458 abstract "Immune checkpoint inhibitors (ICIs) have demonstrated promising efficacy as monotherapy in patients with pulmonary sarcomatoid carcinoma (PSC). We performed the current multi-institutional, real-world study to assess the efficacy of ICIs plus chemotherapy in patients with PSC.All consecutive patients with locally advanced or metastatic PSC from three centers treated with ICIs between January 2018 and July 2021 were enrolled. Programmed death ligand 1 (PD-L1) expression was stained and evaluated using immunohistochemical with 22C3. Single-cell RNA sequencing (scRNA-seq) was performed in two patients with PSC and two patients with adenocarcinoma to understand the cell-type-specific transcriptome landscape of cancer cells and tumor microenvironment (TME) of PSC.A cohort of 42 PSC patients was identified. In the overall population, the objective response rate (ORR) was 73.8%, median progression-free survival (mPFS) was 10.3 months and median overall survival was not reached and 2-year survival rate was 51.2%. For 34 treatment-naïve patients who received first-line ICIs plus chemotherapy, the ORR was 70.6%, mPFS was 10.3 months and 2-year survival rate was 57.8%. In patients with PD-L1 tumor proportion score (TPS) < 1%, 1-49%, and ⩾50%, the ORR was 33.3%, 72.7%, and 85.7% and mPFS was 6.0, 6.7, and 10.3 months, respectively. Notably, two patients with transformed PSC from lung adenocarcinoma after epidermal growth factor receptor-tyrosine kinase inhibitor treatment also responded well to ICIs plus chemotherapy. scRNA-seq revealed immune-cell-inflamed TME, lower intratumoral heterogeneity, and activated immune response pathway in PSC.Our study demonstrated remarkable efficacy of ICIs plus chemotherapy as first-line therapy for patient with locally advanced or metastatic PSC." @default.
• W4310332458 created "2022-12-08" @default.
• W4310332458 creator A5000432967 @default.
• W4310332458 creator A5001322596 @default.
• W4310332458 creator A5007042004 @default.
• W4310332458 creator A5008176130 @default.
• W4310332458 creator A5008421599 @default.
• W4310332458 creator A5014707193 @default.
• W4310332458 creator A5029411467 @default.
• W4310332458 creator A5029637772 @default.
• W4310332458 creator A5037437663 @default.
• W4310332458 creator A5046686348 @default.
• W4310332458 creator A5055029433 @default.
• W4310332458 creator A5057361433 @default.
• W4310332458 creator A5063627915 @default.
• W4310332458 creator A5071199909 @default.
• W4310332458 creator A5073216396 @default.
• W4310332458 creator A5086664284 @default.
• W4310332458 date "2022-01-01" @default.
• W4310332458 modified "2023-09-26" @default.
• W4310332458 title "Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study" @default.
• W4310332458 cites W2019607817 @default.
• W4310332458 cites W2030511761 @default.
• W4310332458 cites W2143124333 @default.
• W4310332458 cites W2228221433 @default.
• W4310332458 cites W2251438188 @default.
• W4310332458 cites W2595413783 @default.
• W4310332458 cites W2796582438 @default.
• W4310332458 cites W2889307896 @default.
• W4310332458 cites W2892640821 @default.
• W4310332458 cites W2946166987 @default.
• W4310332458 cites W2946950110 @default.
• W4310332458 cites W2947247246 @default.
• W4310332458 cites W2971161353 @default.
• W4310332458 cites W2993452673 @default.
• W4310332458 cites W3002579149 @default.
• W4310332458 cites W3009551026 @default.
• W4310332458 cites W3021023953 @default.
• W4310332458 cites W3031018272 @default.
• W4310332458 cites W3080401379 @default.
• W4310332458 cites W3082015854 @default.
• W4310332458 cites W3089256866 @default.
• W4310332458 cites W3092112918 @default.
• W4310332458 cites W3111665711 @default.
• W4310332458 cites W3121111202 @default.
• W4310332458 cites W3134364215 @default.
• W4310332458 cites W3144903047 @default.
• W4310332458 cites W3175096644 @default.
• W4310332458 cites W3189383967 @default.
• W4310332458 cites W3215921195 @default.
• W4310332458 cites W4225374370 @default.
• W4310332458 doi "https://doi.org/10.1177/17588359221136759" @default.
• W4310332458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36419724" @default.
• W4310332458 hasPublicationYear "2022" @default.
• W4310332458 type Work @default.
• W4310332458 citedByCount "2" @default.
• W4310332458 countsByYear W43103324582023 @default.
• W4310332458 crossrefType "journal-article" @default.
• W4310332458 hasAuthorship W4310332458A5000432967 @default.
• W4310332458 hasAuthorship W4310332458A5001322596 @default.
• W4310332458 hasAuthorship W4310332458A5007042004 @default.
• W4310332458 hasAuthorship W4310332458A5008176130 @default.
• W4310332458 hasAuthorship W4310332458A5008421599 @default.
• W4310332458 hasAuthorship W4310332458A5014707193 @default.
• W4310332458 hasAuthorship W4310332458A5029411467 @default.
• W4310332458 hasAuthorship W4310332458A5029637772 @default.
• W4310332458 hasAuthorship W4310332458A5037437663 @default.
• W4310332458 hasAuthorship W4310332458A5046686348 @default.
• W4310332458 hasAuthorship W4310332458A5055029433 @default.
• W4310332458 hasAuthorship W4310332458A5057361433 @default.
• W4310332458 hasAuthorship W4310332458A5063627915 @default.
• W4310332458 hasAuthorship W4310332458A5071199909 @default.
• W4310332458 hasAuthorship W4310332458A5073216396 @default.
• W4310332458 hasAuthorship W4310332458A5086664284 @default.
• W4310332458 hasBestOaLocation W43103324581 @default.
• W4310332458 hasConcept C121608353 @default.
• W4310332458 hasConcept C126322002 @default.
• W4310332458 hasConcept C143998085 @default.
• W4310332458 hasConcept C2776256026 @default.
• W4310332458 hasConcept C2776694085 @default.
• W4310332458 hasConcept C2781182431 @default.
• W4310332458 hasConcept C2908647359 @default.
• W4310332458 hasConcept C71924100 @default.
• W4310332458 hasConcept C90924648 @default.
• W4310332458 hasConcept C99454951 @default.
• W4310332458 hasConceptScore W4310332458C121608353 @default.
• W4310332458 hasConceptScore W4310332458C126322002 @default.
• W4310332458 hasConceptScore W4310332458C143998085 @default.
• W4310332458 hasConceptScore W4310332458C2776256026 @default.
• W4310332458 hasConceptScore W4310332458C2776694085 @default.
• W4310332458 hasConceptScore W4310332458C2781182431 @default.
• W4310332458 hasConceptScore W4310332458C2908647359 @default.
• W4310332458 hasConceptScore W4310332458C71924100 @default.
• W4310332458 hasConceptScore W4310332458C90924648 @default.
• W4310332458 hasConceptScore W4310332458C99454951 @default.
• W4310332458 hasFunder F4320321001 @default.
• W4310332458 hasFunder F4320329745 @default.
• W4310332458 hasLocation W43103324581 @default.

• next